Ozmosi | Cefpirome Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cefpirome

Alternative Names: cefpirome
Clinical Status: Inactive
Latest Update: 2023-09-12
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Bangladesh | Brazil | Bulgaria | China | Dominican Republic | Egypt | India | Indonesia | Ireland | Italy | Korea | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Sri Lanka | Taiwan | Tunisia | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Med. Univ. Wien, Uk für Innere Medizin I
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Abscess

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2011-002758-29

 2011-002758-29

P4

Completed

Unknown

2013-10-04

2022-03-13

Treatments

NCT00280514

 abscess-cef-moxi

P4

Completed

Abscess

2009-12-01

2024-11-27

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

09/12/2023

PubMed

 Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate.

09/01/2022

PubMed

 Enhancement of Acinetobacter baumannii biofilm growth by cephem antibiotics via enrichment of protein and extracellular DNA in the biofilm matrices.

05/26/2022

PubMed

 Evaluation of a Conformationally Constrained Indole Carboxamide as a Potential Efflux Pump Inhibitor in Pseudomonas aeruginosa.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions